Skip to content

Crinetics Pharmaceuticals CRNX Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Viking Therapeutics logo
Viking TherapeuticsVKTX
$0-100%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$1.86M-13.9%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$2.94M-12.8%
LQD
Liquidia CorporationLQDA
$4.36M+5.5%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Corcept Therapeutics logo
Corcept TherapeuticsCORT

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$3.79B+21.9%

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Crinetics Pharmaceuticals's operating lease ROU assets?
Crinetics Pharmaceuticals (CRNX) reported operating lease ROU assets of $39.79M in Q1 2026.
How has Crinetics Pharmaceuticals's operating lease ROU assets changed year-over-year?
Crinetics Pharmaceuticals's operating lease ROU assets decreased by 6.8% year-over-year, from $42.69M to $39.79M.
What is the long-term trend for Crinetics Pharmaceuticals's operating lease ROU assets?
Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's operating lease ROU assets has grown at a 78.5% compound annual growth rate (CAGR), from $2.23M to $40.49M.
What does operating lease ROU assets mean?
This asset represents the company's right to use a leased item, such as office space or data center facilities, over the lease term. It is recognized under modern accounting standards to reflect the financial commitment of long-term operating leases. It provides visibility into the company's fixed operational footprint.